BioRN Lounge: Dr. Juergen Gamer talked about Apogenix attractive immuno-oncology pipeline.
BioRN Lounge: Dr. Juergen Gamer talked about “TNF Superfamily Receptor Modulators – Innovative Immuno-oncology Therapeutics”
Once again, the BioRN Lounge was the occasion for the life science companies as well for scientists from our research institutes, to meet and chat about latest news and achievements. The BioRN Lounge is the prime monthly networking event for BioRN members. It is the occasion for exchange, meeting and interaction in a very relaxed atmosphere with some drinks and food.
In addition, an invited speaker from the network presents and discusses with the participants, scientific trends, outbreaking techniques, outstanding research and more. Yesterday the Lounge event hosted Juergen Gamer, VP Business Development, at Apogenix AG and strategic advisory board member at BioRN e.V..
Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signalling pathways, thereby restoring the anti-tumour immune response.
Dr. Juergen Gamer guided the audience into the immune-oncology world starting from the adventure of PD-1 inhibitors. It took 22 years for researchers to bring the PD-1 inhibitors from the bench to the bedside. Now we can count on 5 approved inhibitors on the market, 126 under development and c.ca 1300 active clinical trials.
“The PD-1 inhibitors adventure should teach researchers in the immune-oncology field and beyond, to simply never give up”
Since the immune systems response is very different depending on the tumour type, PD-1 inhibitors are not the “magic bullet” said Dr. Gamer, and therefore Apogenix is focusing on other T-cells targets and therapies combination.
Dr. Gamer focused his presentation on the HERA-ligands (TNF superfamily receptor agonists) and asunercept (CD95 receptor) and presented the promising results in pre-clinical and clinical studies. Apogenix’ lead drug candidate asunercept -for example, is being developed for the treatment of solid tumors and malignant hematological diseases and has been evaluated in the treatment of glioblastoma and myelodysplastic syndromes (MDS).
Dr. Gamer pointed out several times during his presentation, the relevance of Apogenix’ collaboration with global healthcare industries for clinical studies, and with academia for the investigation of basic mechanism of action of the developed drugs.
BioRN is a life science research and industry cluster dedicated to the development of cell-specific, molecular and personalised innovative treatments. The BioRN Cluster stands for the development, networking, representation and promotion of the life science region into one of the leading life science clusters in Europe.
The cluster-members include renowned academic research institutions such as the Universities of Heidelberg, the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL) and big pharmaceutical companies such as AbbVie, Boehringer Ingelheim, Johnson & Johnson, Merck, Roche, und Sanofi-Aventis, and about 80 small and medium-sized biotech enterprises. Beyond the members registered in the cluster, BioRN gives access to a wider network via partnerships and collaborations.
In terms of the use of clusters for the internationalization of companies, BioRN has founded, together with Leuven (Belgium), Maastricht (Netherlands) and Copenhagen (Denmark), an alliance for the enforcement of biomedical innovation in Europe, called the Health Axis Europe.
About Apogenix AG
Since the company’s foundation in 2005, the Apogenix team has developed a promising portfolio of innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. These protein therapeutics target critical pathways involved in the proliferation, migration, and apoptosis of diseased cells and have the potential to transform the treatment of oncological and malignant hematological diseases.